Amebiasis, due to the pathogenic parasite *Entamoeba histolytica*, is a leading cause of diarrhea globally. Largely an infection of impoverished communities in developing countries, amebiasis has emerged as an important infection among returning travelers, immigrants, and men who have sex with men residing in developed countries. Severe cases can be associated with high case fatality. Polymerase chain reaction–based diagnosis is increasingly available but remains underutilized. Nitroimidazoles are currently recommended for treatment, but new drug development to treat parasitic agents is a high priority. Amebiasis should be considered before corticosteroid therapy to decrease complications. There is no effective vaccine, so prevention focuses on sanitation and access to clean water. Further understanding of parasite biology and pathogenesis will advance future targeted therapeutic and preventative strategies.

**Keywords.** amebiasis; diarrhea; colitis; burden; PCR; HIV; MSM.

Amebiasis is caused by infection with the pseudopod-forming, nonflagellated protozoan parasite *Entamoeba histolytica*. Amebiasis can be asymptomatic or can lead to the development of severe infection with amebic colitis and amebic liver abscess. The significance of amebiasis is exemplified in several ways. Amebic colitis is a leading cause of severe diarrhea worldwide and is listed among the top 15 causes of diarrhea in the first 2 years of life in children living in the developing world, where diarrhea remains the third leading cause of death, accounting for 9% of all deaths in children under the age of 5 years [1–3]. Fulminant amebic colitis is an uncommon complication of amebiasis but is associated with high mortality, and on average more than 50% with severe colitis die [4]. *E. histolytica* is classified as a category B priority biodefense pathogen by the National Institute of Allergy and Infectious Diseases (NIAID) because of its low infectious dose, chlorine resistance, and environmental stability, properties that can pose a threat of easy dissemination through contamination of food and water supplies. Even in low-incidence settings, these properties of the parasite lead to outbreaks among military and general populations [5–7]. In addition, *E. histolytica* is one of the most common causes of infectious diarrhea among travelers returning from endemic areas [8].

Advances in molecular diagnostic methodologies have improved our understanding and led to the recognition and separation of *E. histolytica* from nonpathogenic species of *Entamoeba*. Of the many *Entamoeba* species that infect humans, 3 species are morphologically indistinguishable from *E. histolytica*. Of these 3, *E. moshkovskii* may cause diarrhea, whereas *E. dispar* and the newly described *E. bangladeshi* are considered nonpathogenic [9]. Earlier descriptions of amebiasis relying solely on microscopy may have been obscured by these nonpathogenic strains. There is no vaccine to prevent amebiasis. Nitroimidazoles are the mainstay treatment for invasive amebiasis. Given the toxicity that can be associated with this class and potential concerns for development of resistance, as has already been reported for some anaerobic pathogens, new therapies are needed [10]. In addition, the NIAID has set priorities for drug development for treatment of category B pathogens. For these reasons, improved understanding of amebiasis pathogenesis is needed as a way forward toward enhanced treatment and prevention. This report reviews recent literature expanding our knowledge of the epidemiology, clinical presentation, and management of amebiasis, while providing important new insights into diagnostic evaluation and prevention.

**EPIDEMIOLOGY**

**Global Burden**

The global significance of amebiasis is widespread, with the highest burden of amebiasis borne by those residing in developing countries, particularly the tropics and subtropics, where there is inadequate hygiene and access to sanitation. Millions
of people are infected with *E. histolytica*, making amebic colitis a leading cause of diarrhea, estimated to kill more than 55,000 people each year [1]. Amebiasis is endemic in developing parts of Central and South America, Africa, and Asia. In the United States, the incidence of amebiasis is low, though amebiasis-related deaths still routinely occur, accounting for at least 5 deaths per year [11]. Amebiasis in the United States is seen mostly in returning travelers or immigrants from endemic countries [12]. Data from the GeoSentinel Surveillance Network, a large international surveillance and monitoring system, have shown that *E. histolytica* is the third most frequently isolated pathogen among returning travelers with infectious gastrointestinal disease. Amebiasis accounts for 12.5% of all microbiologically confirmed cases, with an estimated incidence of 14 in every 1000 returning travelers [8]. Travelers to South Asia, the Middle East, and South America appear to have the highest risk, in particular those volunteering as missionary workers or doing other volunteering work. Even travel of household or sexual contacts to an endemic area may pose a risk of infection [13]. Other industrialized countries including parts of Asia, Europe, North America, and Australia have highlighted gay men, bisexual men, and other men who have sex with men (MSM) as a population at higher risk of acquiring amebiasis than the general population. Recent reports from Taiwan and Japan, for example, have shown high rates of invasive amebiasis in HIV-infected MSM [14, 15]. In developing countries, the exact burden of amebiasis is difficult to quantify, and reports can be affected by geographic region, study design, sample size, incubation, symptom severity, and the sensitivity of the diagnostic modality used (Table 1). In addition, diagnostic capacities and surveillance are often limited in areas where *E. histolytica* is endemic. Recent reports, however, have shown that the seroprevalence of *E. histolytica* in some rural communities of Mexico remains as high as 42% [16]. In an urban slum of Dhaka, Bangladesh, 11% of children had an episode of amebic diarrhea in the first year of life [17]. By cross-sectional survey, *E. histolytica* was detected using polymerase chain reaction (PCR) in 13.7% of fecal samples in northeast states of India [18]. *E. histolytica* seroprevalence was found to be 11% among 7 provinces of China and was as high as 41% among MSM in the provinces of Beijing and Tianjin [19, 20]. A re-emergence of *E. histolytica* infection was described in Jeddah, Saudi Arabia, among children under the age of 16 years presenting to the hospital with acute gastroenteritis. Using fecal antigen detection, *E. histolytica* was found to be the most prevalent enteropathogen associated with diarrhea, with a prevalence of 20% [21]. The epidemiology on the incidence and prevalence of amebiasis in Africa is particularly limited, but it appears widespread, as exemplified in a cross-sectional study of patients attending gastroenterology clinics in South Africa, where *E. histolytica* was detected by PCR in 8.5% of fecal samples [22].

### Table 1. Recent Prevalence Estimates of *Entamoeba histolytica* Infection by World Regions

| Country                                     | f, %  | Method          | Study Characteristics                                      | Ref.   |
|---------------------------------------------|-------|-----------------|------------------------------------------------------------|--------|
| Latin America and Caribbean                 |       |                 |                                                            |        |
| Durango, Mexico                             | 42    | AB              | Cross-sectional serosurvey among rural communities         | [16, 48]|
| Asia Pacific                                |       |                 |                                                            |        |
| Beijing and Tianjin, China                  | 41    | AB              | Cross-sectional serosurvey of men who have sex with men    | [20]   |
| CDC, China                                  | 11    | AB              | Cross-sectional serosurvey of the general population       | [19]   |
| Lahore, Pakistan                            | 17    | AG              | Cross-sectional survey among 3 different socioeconomic strata | [49]   |
| Northeast, India                            | 14    | PCR             | Cross-sectional survey                                     | [18]   |
| Dhaka, Bangladesh                           | 11    | PCR             | Prospective birth cohort study of infants followed for 1 year | [17]   |
| Selangor, Malaysia                          | 8     | PCR             | Cross-sectional survey of selected ethnic groups           | [50]   |
| Sydney, Australia                           | 5     | AB              | Retrospective study of HIV-infected men who have sex with men | [51]   |
| Mirzapur, Bangladesh                        | 3     | AG              | Multinational case-control study of children <6 years with MSD | [23]   |
| Vellore, India and Naushahro Feroze, Pakistan | 1*    | AG              | Multinational prospective birth cohort study of children followed for 2 years to determine the adjusted attributable fraction of diarrhea | [52]   |
| Europe                                      |       |                 |                                                            |        |
| Turkey                                      | 32    | AG              | Prevalence study among patients presenting with ulcerative colitis | [53]   |
| Middle East                                 |       |                 |                                                            |        |
| Jeddah, Saudi Arabia                        | 20    | AG              | Cross-sectional study of children hospitalized with acute diarrhea | [21]   |
| Yemen                                       | 20    | PCR             | Community-based cross-sectional survey                      | [54]   |
| Africa                                      |       |                 |                                                            |        |
| Cairo, Egypt                                | 38    | AG              | Case-control study of patients presenting with acute diarrhea | [55]   |
| Vhembe, South Africa                        | 34    | AB              | Cross-sectional serosurvey                                 | [56]   |
| Giyani and Soshangwe, South Africa          | 9     | PCR             | Cross-sectional study of patients attending gastroenterology clinic | [22]   |

Abbreviations: AB, serology; AG, stool antigen detection; CDC, Chinese Center of Disease Control and Prevention (7 provinces of China including Guangxi, Qinghai, Guizhou, Shanghai, Sichuan, Sankiang, and Beijing); f, frequency; MSD, moderate to severe diarrhea; PCR, stool detection by polymerase chain reaction.

*In year 2 of life.*
(GEMS), *E. histolytica* was 1 of the top 10 causative agents of moderate to severe diarrhea in children under the age of five years in 2 of their 7 study sites across sub-Saharan Africa and South Asia. In addition, *E. histolytica* diarrhea was associated with a relatively greater risk of death across all GEMS sites and was the enteric pathogen with the highest hazard ratio for death in the second year of life [23]. Recent re-analysis of specimens from GEMS, to reassess estimates of pathogen-specific diarrhea exclusively using PCR diagnostics, showed that *E. histolytica* was 1 of the top 7 pathogens causing dysentery, with the most frequent cause of dysentery led by the combined group of *Shigella* species and enteroinvasive *Escherichia coli* [2]. In summary, the global impact of amebic infection remains significant, though challenging to quantify with precision given several methodologic and epidemiologic complexities, but prevalence estimates remain as high as 40% in some populations (Table 1).

**Transmission**

The life cycle of *E. histolytica* is simple, with only 2 stages, existing as either an infectious cyst or invasive trophozoite (Figure 1). Transmission occurs after the ingestion of the infectious cyst. This most commonly arises from fecally contaminated hands, food, or water, but there is a new appreciation that exposure to fecal matter may occur during sexual contact, in particular among MSM groups [24]. Following ingestion, excystation to trophozoites occurs, and the released trophozoites migrate to the large intestine, multiplying by binary fission to produce more cysts. The trophozoite may invade the intestinal epithelium and even pass to extra-intestinal sites such as the liver via hepatic portal circulation or disseminate further to distant sites such as the brain and lungs hematogenously. Symptoms may occur within weeks after ingestion but may also develop years after infection.

Cysts and trophozoites are passed in stools. Several properties of the cyst help it to remain hardy in the environment for weeks, whereas trophozoites do not survive. For example, cysts are resistant to gastric acidity and are also relatively resistant to chlorine. The low infectious dose and environmental stability can predispose to the development of outbreaks [5, 6]. Cysts can be killed by boiling.

**PATHOGENESIS**

*E. histolytica* pathogenesis can be characterized by 3 events: host cell death, inflammation, and parasite invasion. Contact with host cells is required for parasite-induced death. Adherence is mediated through the parasite Gal/GalNAc lectin adhesion molecule. Trophozoites are able to kill host cells by several different mechanisms, which include inducing programmed cell death, phagocytosis, and trogocytosis [25].

*E. histolytica* causes inflammation of the colon, termed amebic colitis. The intestinal epithelium is the point of first contact for *E. histolytica*. Before cell adherence, trophozoites secrete immune modulators that stimulate epithelial cells, resulting in

---

**Figure 1.** *Entamoeba histolytica* in stool and pathological features of intestinal amebiasis. A, Cyst of *E. histolytica/E. dispar* stained with trichrome. Note the chromatoid body with blunt ends (red arrow). B, Trophozoite of *E. histolytica* with ingested erythrocytes stained with trichrome. The ingested erythrocytes appear as dark inclusions (red arrow). The parasite shows nuclei that have the typical small, centrally located karyosome and thin, uniform peripheral chromatin. C, Intestinal tissue from a patient with amebic colitis showing multiple ulcers. D, Classic flask-shaped ulcer of amebiasis (courtesy of the Centers for Disease Control and Prevention).
cytokine production and subsequent mucosal inflammatory cell infiltration [26, 27]. *E. histolytica*, like several pathogenic protozoa, secretes a protein homolog of the proinflammatory cytokine macrophage migration inhibitory factor (EhMIF). A positive correlation was recently found between *EhMIF* levels and intestinal inflammation in persons with amebic colitis [28]. It would seem counterintuitive for parasites to produce a molecule like *EhMIF*; however, *E. histolytica* has developed a number of mechanisms to evade the immune response and persist in the host [27]. Also, *E. histolytica* exploits the inflammatory response to promote its own invasion. *EhMIF*-induced inflammation results in increased production in matrix metalloproteinases (MMPs) [28]. MMPs break down the extracellular matrix in the gut to promote cell migration and are overexpressed in all infections with protozoan parasites, including amebiasis [29, 30]. In a recent study, MMPs were shown to be necessary for *E. histolytica* tissue invasion [31]. It appears that *EhMIF* is a parasite virulence factor that triggers inflammation, resulting in increased expression of MMPs, which promotes invasion of the host.

**IMMUNE RESPONSE**

Various host immune mechanisms are elicited in response to amebiasis in an attempt to clear or prevent infection. Interferon gamma (IFN-γ) appears to provide protection from amebiasis, as children with higher IFN-γ had a significantly lower incidence of future *E. histolytica* diarrhea [32]. Also, protection from amebiasis includes acquired immunity from antibodies against the amebic antigens Gal/GalNAc lectin and *EhMIF*. Infected children develop antibodies against *EhMIF*, which are associated with protection from reinfection [28, 33]. Although the immune response is normally protective, it can also produce undesirable effects when the response is excessive. For example, higher TNF-α production was shown to correlate with *E. histolytica* diarrhea in children. Another cytokine produced during infection is interleukin-8 (IL-8), a potent neutrophil chemoattractant. In response to IL-8, neutrophils infiltrate the intestinal tract as the first cells of an innate immune response to amebic invasion [27, 30]. Patients with severe amebic colitis have higher colonic tissue levels of IL-8 and neutrophils, suggesting that neutrophils might be responsible for collateral tissue damage during inflammation at the site of invasion [34–36].

**CLINICAL MANIFESTATIONS**

The majority of *E. histolytica* infections are asymptomatic; only about 10%–20% progress to develop symptomatic infection. The reasons for this are poorly understood but result from an interplay of several factors related to parasite, host, and environment. Recently, it was found that the gut microbiome is enriched in *Prevotella copri* in people with amebic diarrhea, indicating that dysbiosis may in part contribute to susceptibility to the development of colitis [22].

### Intraluminal Amebiasis

Asymptomatic infection is referred to as luminal amebiasis. Screening for asymptomatic infection should be considered in those with a personal history of travel to/immigration from an endemic area or a history of this in either a household or sexual contact. A gender difference in amebiasis is not seen in children, but interestingly, in the adult population, invasive disease is more common in males than females, particularly for amebic liver abscess [12].

### Amebic Colitis

Symptomatic intestinal infection can have a wide spectrum of manifestations (Table 2). One hallmark of amebic colitis is diarrhea, which may be watery or bloody and present with abdominal cramps, pain/tenderness, and weight loss. Presentation may be acute or more gradual, and amebic colitis may also present similarly to inflammatory bowel disease (IBD). It may not be possible to distinguish amebic colitis from IBD even by imaging, inflammatory markers, or endoscopy, and the colon may appear friable, with diffuse ulceration by gross examination (Figure 1) [4]. Disease may be limited to the ascending colon or cecum. Life-threatening manifestations of amebic colitis include fulminant infection, which can result in massive areas of colonic involvement with perforation and peritonitis, bowel necrosis, or toxic megacolon [4]. Corticosteroid use has been described as a risk factor for the development of fulminant forms of amebic colitis [4]. Patients may be toxic in appearance, febrile, and hypotensive, with profuse bloody diarrhea, abdominal pain, distension, and signs of peritonism. The case fatality of fulminant amebic colitis ranges from 40% to 89%. Toxic

### Table 2. Clinical Findings in Amebic Colitis and Amebic Liver Abscess

| Characteristic | Amebic Colitis | Amebic Liver Abscess |
|---------------|---------------|---------------------|
| Migration from or travel to an endemic area | ++++ | ++++ |
| Diarrhea | ++++ | ++ |
| Heme-positive stools | +++ | - |
| Abdominal pain | ++++ | ++++* |
| Hepatomegaly | - | ++ |
| Weight loss | ++ | ++ |
| Fever >38°C | + | +++ |
| Cough | - | ++ |
| Leukocytosis | +/- | ++++*b |
| Elevated alkaline phosphatase | - | ++++ |
| Sigmoidoscopy/colonoscopy | Friable colonic mucosa with discrete ulcers | - |

| Abdominal imaging (ultrasound, CT, or MRI) | Colonic inflammation and bowel wall thickening | Intrahepatic lesion typically right lobe, often solitary |

++++, ≥75%, ++++, 50–74%, ++, 25–49%, +, <25%, +/- variable.

*Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.

*pain is located in the right upper quadrant in amebic liver abscess.

bTransaminase enzymes may also be elevated in amebic liver abscess.
megacolon has been described in a patient with amebic colitis and heavy use of the antimotility agent loperamide [37]. Other implicated risk factors for fulminant disease include diabetes mellitus, alcoholism, malignancy/chemotherapy, and pregnancy [4]. Amebic colitis may also present as acute appendicitis (Figure 2). Appendicitis was noted in up to 15% of Japanese HIV-infected patients presenting with appendicitis and undergoing appendectomy [38]. The only distinguishing feature was a higher median neutrophil count in those with amebic infection compared with those without in this series [38]. Ameboma, the development of tumor-like granulation tissue in the colonic lumen, can mimic colonic cancer. The differential diagnosis of amebic colitis includes bacterial enteric infection, such as Salmonella spp., Shigella spp., Campylobacter spp., enterohemorrhagic E. coli, enteroinvasive E. coli, Clostridium difficile infection, IBD, and other noninfectious causes of colitis. The aid of stool PCR and culture can help to distinguish several of these differentials.

**Disseminated Amebic Disease**

Amebic liver abscess, which is the most common extra-intestinal manifestation, develops when trophozoites disseminate to the liver. For poorly understood reasons, amebic liver abscesses are 10 times more common in men than women, often presenting between the ages of 20 and 40 years. Onset can be acute, subacute, or subtle. Hepatic amebiasis has been reported over 20 years after the last visit to an endemic area, so any travel history may be important in this diagnosis. The majority will present with fever and right upper quadrant pain, typically without concurrent dysentery or gastrointestinal symptoms (Table 2) [12]. Hepatomegaly with point tenderness over the liver can often be detected. Cough and respiratory symptoms, including pleuritic right-sided chest pain, may occur, or even referred pain to the shoulder. Elevated alkaline phosphatase and peripheral leukocytosis, usually in the range of 12,000–20,000/mm³, is seen, though typically without eosinophilia. Imaging more often reveals right lobe lesions, usually solitary, but left lobe or multiple lesions may be less commonly seen (Table 2) [12]. Amebic liver abscess may be difficult to clinically distinguish from pyogenic liver abscess. Echinococcal cysts of the liver are another important differential, but they tend to appear as multiple clustered fluid collections without surrounding enhancement on imaging. Peripheral eosinophilia is rare with amebic liver abscess and is more commonly associated with echinococcosis and hepatic fascioliasis (liver fluke). Detection of bacteremia by blood culture, stool studies, and serology will also help to narrow the differential. Occasionally, diagnostic or therapeutic aspiration is required. Aspiration of the amebic liver abscess reveals “anchovy paste,” chocolate-colored fluid consisting of necrotic hepatocytes.

Pleuropulmonary amebiasis can occur as a complication of ruptured amebic liver abscess, presenting with pneumonitis or lung abscess. Intraperitoneal rupture is rare but can be life-threatening if there is pericardial involvement. Trophozoites may also on occasion disseminate hematogenously to the central nervous system and other extra-intestinal sites [39].

**LABORATORY DIAGNOSIS**

A number of diagnostic modalities are available to assist with diagnosis, including microscopy, antigen detection, molecular tests, and serology (Table 3). Often a combination of tests is required to establish diagnosis. Traditionally, microscopy has been the most widely used but has limited diagnostic utility and is no longer recommended as a reliable way to diagnose amebiasis. Most cases of extra-intestinal abscess occur without concurrent intestinal infection, resulting in lower sensitivity of stool studies for the diagnosis of amebic liver abscess.

**Stool Microscopy**

Cysts and trophozoites can be visualized by an experienced eye, sometimes with evidence of hemophagocytosis. Fresh stools increase the recovery of both trophozoites and cysts and can be prepared as either wet mounts or stained preparations. Mature cysts have 4 nuclei measuring about 12–15 µm in diameter. Trophozoites have a single nucleus and are slightly larger, measuring about 15–20 µm. Microscopy should not be used when other modalities are accessible.

**Stool Antigen Detection**

Antigen detection tests have helped to overcome some of the limitations of stool microscopy and are easy to use, but in practice have variable sensitivity and specificity, particularly in low-endemic areas [40]. Although several EIA kits are commercially available, they are not as widely available in resource-limited settings. The Techlab E. histolytica II test (Blacksburg, VA), which detects E. histolytica–derived Gal/GalNAc-specific lectin, can exclude nonpathogenic E. dispar, as can the Cellabs CELISA Path

---

**Figure 2.** Amebic colitis. Immunohistochemical staining of trophozoites (brown) using specific anti–Entamoeba histolytica macrophage migration inhibitory factor antibodies in a patient with amebic appendicitis.
A false-negative EIA test was reported from Spain, possibly from interference, as the result turned positive with subsequent testing [41]. Recently, an E. HISTOLYTICA QUIK CHEK immunochromatographic (IC) assay, which is simple to perform and has a quick turnaround time, was approved by the US Food and Drug Administration (FDA).

Stool Molecular Studies
Stool PCR is extremely sensitive. It is considered the gold standard for diagnosis of amebiasis and is becoming readily available through FDA-cleared gastrointestinal panels that simultaneously detect multiple enteropathogens, such as the BD Max Enteric Parasite Panel (Becton, Dickinson and Company, Sparks, MD), the Lumix xTAG Gastrointestinal Pathogen Panel (Luminex Corporation, Toronto, Canada), and the Biofire FilmArray Gastrointestinal Panel (BioFire Diagnostics, Salt Lake City, UT) [42]. The use of PCR is also endorsed by the World Health Organization, but the expense and requirement for technical expertise may limit use in resource-limited settings [43]. Purulent fluid aspirated from liver abscess can also be tested.

Serology
Serology is a useful adjunct to stool studies. Several EIA kits for antibody detection are commercially available, including indirect fluorescence, immunoelectrophoresis, and immunosorbent assays, but the indirect hemagglutination test has been replaced by EIA. Antibody detection is particularly helpful in the diagnosis of extra-intestinal disease, when stool studies may be negative. False-positive results have been reported [12]. Antibodies remain detectable for years after successful treatment, so it is difficult to reliably distinguish between active and past infection.

Other Diagnostic Methods
Amebic ulcers most often develop in the cecum. Histology obtained by diagnostic endoscopic biopsy or surgical resection may show the characteristic flask-shaped ulcer (Figure 1). Trophozoites may be identified at the edge of the ulcer or within the tissue, using periodic acid-Schiff staining or immunoperoxidase staining with specific anti-E. histolytica antibodies (Figure 2).

Imaging
Ultrasoundography, abdominal computed tomography (CT), and magnetic resonance imaging are all good modalities to detect liver abscess. By ultrasound, a cystic intrahepatic hypoechogenic lesion can be found. By CT, an abscess with a nonenhancing center surrounded by a rim of inflammation can be seen following contrast administration. The detection of a space-occupying lesion in the liver and positive amebic serology supports the diagnosis of amebic liver abscess.

THERAPY
All patients with amebiasis should be treated (Table 4). Patients with clinical disease require treatment with 2 drugs: an amebicidal tissue-active agent and a luminal cysticidal agent. Those with asymptomatic amebiasis need only be treated with a luminal cysticidal agent to prevent invasion and transmission.
The amebicidal agents include metronidazole and tinidazole, which are both nitroimidazole agents. They are highly effective at eliminating invading trophozoites and remain the recommended therapy for amebic colitis and amebic liver disease. Tinidazole has a longer half-life and is better tolerated, but metronidazole is as effective at clearing parasites [44]. Side effects of metronidazole include nausea, headache, anorexia, metallic taste, peripheral neuropathy, and disulfiram-like reaction with alcohol. The nitroimidazoles do not effectively eradicate luminal cysts and must be followed by a luminal agent. The thiazolide agent nitazoxanide, with reputed broad-spectrum antimicrobial properties, was shown in a small single-center trial from Egypt to have clinical and microbiologic response in patients treated for hepatic and intestinal amebiasis of >90%. However, the unexpectedly high response rate in the placebo group of 40%–50% raises methodologic concerns [45].

Auranofin, a gold compound that has been used to treat selective cases of rheumatoid arthritis, has entered into early clinical drug development as an antiparasitic agent, but further study is needed to determine if it will be an effective treatment of amebiasis and whether known safety concerns such as diarrhea, rash, and bone marrow suppression will limit its use [47].

### PREVENTION

There is no vaccine to prevent amebiasis. The focus of primary preventative efforts, therefore, remains food and water safety, attention to hand hygiene, and avoidance of fecal–oral exposure, including through sexual practices. Before travel to endemic areas such as Asia, Mexico, South America, and sub-Saharan Africa, patients should be advised on food safety to prevent enteric illness. Patients, especially MSM, should also be advised to avoid sexual practices that may lead to fecal–oral transmission. Patients should be asked about prior travel and screened appropriately for secondary prevention. Even a remote travel history is important, as amebic liver abscess and fulminant amebic colitis could occur years after travel. Household contacts of patients with amebiasis should be screened, as amebiasis may spread among family and household contacts [4]. Patients with a new diagnosis of IBD who have traveled to an endemic area should be screened as well, as fulminant amebic colitis may ensue if patients are administered corticosteroid or other immunosuppressive therapy with misdiagnosis [4]. Use of loperamide should be avoided in amebic colitis [37].

### Table 4. Antiparasitic Therapy for Entamoeba histolytica Infection

| Drug of Choice | Daily Dose | Duration, d | Alternatives |
|----------------|------------|-------------|--------------|
| **Tissue-active agent** | | | |
| **Amebic colitis**<sup>a</sup> | Metronidazole or | 750 mg po TID (35–50 mg/kg/d divided TID) | 5–10 | Nitazoxanide<sup>b</sup> |
| | Tinidazole | 2 g po once daily (50 mg/kg once daily) | 3–5 | |
| **Amebic liver abscess and disseminated amebic disease**<sup>a</sup> | Metronidazole or | 750 mg po TID (35–50 mg/kg/d divided TID) | 10 | - |
| | Tinidazole | 2 g po once daily (50 mg/kg once daily) | 5 | |
| **Luminal agent** | | | |
| **Asymptomatic carriage or following tissue-active agent** | Paromomycin | 25–35 mg/kg/d by mouth divided TID | 7 | Iodoquinol/diiodohydroxyquinolinediloxanide furoate<sup>c</sup> |

**Abbreviations:** BID, twice daily; IV, intravenous; po, by mouth; TID, three times daily.

<sup>a</sup>Severe disease or unable to tolerate oral therapy, use metronidazole 1500 mg IV divided TID (75–30 mg/kg/d divided TID) [46].

<sup>b</sup>Limited data, 500 mg po BID (≥12 years), 200 mg BID (age 4–11 years), or 100 mg BID (age 1–3 years) for 3 days.

<sup>c</sup>Iodoquinol 650 mg po TID (30–40 mg/kg/d po divided TID for children) for 20 days after meals (optic neuritis and peripheral neuropathy have been reported), diloxanide furoate 500 mg po TID (20 mg/kg/d po divided TID for children) for 10 days [57].
CONCLUSION
Amebiasis remains one of the most significant enteropathogens worldwide. Advances in molecular epidemiology and pathogenesis have advanced our understanding of this parasite; however, many gaps in knowledge remain. In addition, although efforts are ongoing, there is no vaccine and only a single effective drug class. Prevention remains challenging, highlighting the need for improved awareness of this infection and novel therapeutic and preventative strategies.

Acknowledgments
We acknowledge Dr. William A. Petri, Jr., for helpful advice. We apologize to all colleagues we were unable to cite due to space limitations.

Author contributions. S.M. and D.A.S. developed the concept and design of the project. D.A.S. prepared the first draft of the manuscript. S.M., L.F., K.W., and D.A.S. revised the manuscript.

Financial support. This work was supported by the National Institutes of Health (NIH; R01AI026649-5K08AI119181), the Robert Wood Johnson Foundation–Harold Amos Medical Faculty Development Program Award (to S.M.), the Emerging Infectious Diseases Project of Japan from the Japan Agency for Medical Research and Development (AMED), and a grant from the National Center for Global Health and Medicine (29–2013; to K.W.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095–128.
2. Liu J, Platts-Mills TA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhea in children: a reanalysis of the GEMS case-control study. Lancet 2016; 388:1291–301.
3. UNICEF. Current status and progress: diarrhea remains a leading killer of young children, despite the availability of a simple treatment solution. https://data.unicef.org/topic/child-health/diarrhoeal-disease/. Updated March 2018. Accessed April 4, 2018.
4. Shirley DA, Moonah S, Fulminiari amebic colitis after corticosteroid therapy: a systematic review. PLoS Negl Trop Dis 2016; 10:e0004879.
5. Kasper MR, Lescano AG, Lucas C, et al. Diarrhea outbreak during U.S. military training in El Salvador. PLoS One 2012; 7:e40404.
6. Escola-Verge L, Arando M, Vall M, et al. Outbreak of intestinal amoebiasis among men who have sex with men, Barcelona (Spain), October 2016 and January 2017. Euro Surveill. In press.
7. Salt IE, Khairnar K, Gough K, Pillai DR. A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain. Clin Infect Dis 2009; 49:346–53.
8. Swaminathan A, Torri JL, Slagenhaut P, et al. GeoSentinel Network. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 2009; 59:19–27.
9. Shimokawa C, Kabir M, Tanouchi M, et al. Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis 2012; 206:744–51.
10. Paulish-Miller TE, Augustini P, Schuyler JA, et al. Trichomonas vaginalis metronidazole resistance is associated with single nucleotide polymorphisms in the nitroreductase genes ntrE1v and ntrE1v. Antimicrob Agents Chemother 2014; 58:2938–43.
11. Gunther J, Shafir S, Bristow B, Sorvillo F. Short report: amebiasis-related mortality among United States residents, 1990–2007. Am J Trop Med Hyg 2011; 85:1038–40.
12. Cordel H, Prendki V, Madec Y, et al. ALA Study Group. Imported amoebic liver abscess in France. PLoS Negl Trop Dis 2013; 7:e2333.
13. Forteza A, Ballesta Ruiz C, Veyvereva G, et al. Resolution of refractory thrombotic thrombocytopenic purpura (TTP) after successful treatment of a fulminant colitis due to Entamoeba histolytica. Gastroenterol Hepatol 2013; 36:294–5.
14. Hung CC, Ji DD, Sun HY, et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis 2008; 2:e175.
15. Watanabe K, Gatanaga H, Escueta-de Cadiz A, et al. Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy. PLoS Negl Trop Dis 2011; 5:e1318.
16. Alvarado-Esquivel C, Hernandez-Tinoco J, Sanchez-Anguiano LF. Seroprevalence of Entamoeba histolytica infection in general population in rural Durango, Mexico. J Clin Med Res 2015; 7:345–9.
17. Mondal D, Mimak J, Alam M, et al. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin Infect Dis 2012; 54:185–92.
18. Nath J, Ghosh SK, Singh B, Paul J. Molecular epidemiology of amebiasis: a cross-sectional study among North East Indian population. PLoS Negl Trop Dis 2015; 9:e0004225.
19. Yang B, Chen Y, Wu L, et al. Seroprevalence of Entamoeba histolytica infection in China. Am J Trop Med Hyg 2012; 87:97–103.
20. Zhou F, Li M, Li X, et al. Seroprevalence of Entamoeba histolytica infection among Chinese men who have sex with men. PLoS Negl Trop Dis 2013; 7:e2232.
21. Hegazi MA, Patel TA, El-Deek BS. Prevalence and characteristics of Entamoeba histo- lytica infection in Saudi infants and children admitted with diarrhea at 2 main hospitals at South Jeddah: a re-emerging serious infection with unusual presentation. Braz J Infect Dis 2013; 17:32–40.
22. Ngobeni R, Samie A, Moona S. Entamoeba in South Africa: correlations with the host microbiome, parasite burden and first description of E. bangladeshi outside of Asia. J Infect Dis 2017; 216:1592–600.
23. Kotloff KL, Nataro JP. Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in children and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209–22.
24. Hung CC, Chang SY, Ji DD. Entamoeba histolytica infection in men who have sex with men. Lancet Infect Dis 2012; 12:279–36.
25. Ralston KS, Solga MD, Mackey-Lawrence NM, et al. Tegrotocystis by Entamoeba histolytica contributes to cell killing and tissue invasion. Nature 2014; 508:526–30.
26. Yu Y, Chadee K. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact. Gastroenterology 1997; 112:1536–47.
27. Moona SN, Jiang NM, Petri WA Jr. Host immune response to intestinal amebiasis. PLoS Pathog 2013; 9:e1003489.
28. Ngobeni R, Abhyankar MM, Jiang NM, et al. Entamoeba histolytica-encoded homolog of macrophage migration inhibitory factor contributes to mucosal inflammation during amebic colitis. J Infect Dis 2017; 215:1294–302.
29. Geurts N, Opdenakker G, Van den Steen PE. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 2012; 133:257–79.
30. Peterson KM, Guo X, Elkahlonou AG, et al. The expression of REG 1A and REG 1B is increased during acute amebic colitis. Parasitol Int 2011; 60:296–300.
31. Thibeaux R, Avé P, Bernier M, et al. The parasite Entamoeba histolytica exploits the activities of human matrix metalloproteinases to invade colonic tissue. Nat Commun 2014; 5:5142.
32. Haque R, Mondal D, Shu J, et al. Correlation of interferon-gamma production by peripheral blood mononuclear cells with childhood malnutrition and susceptibility to amebiasis. Am J Trop Med Hyg 2007; 76:340–4.
33. Haque R, Ali IM, Sack RB, et al. Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. J Infect Dis 2001; 183:1787–93.
34. Ventura-Juárez J, Barba-Gallardo LF, Muñoz-Fernández L, et al. Immunohistochemical characterization of human fulminant amebic colitis. Parasite Immunol 2009; 31:384–9.
35. Dickson-Gonzalez SM, de Uribe ML, Rodríguez-Morales AJ, Polymorphonuclear neutrophil infiltration intensity as consequence of Entamoeba histolytica infection. Braz J Infect Dis 2013; 17:32–40.
36. Kobayashi T, Watanabe K, Yano H, et al. Underestimated amoebic appendicitis and a possible role of amebiasis as a cause of appendicitis. J Infect Dis 2009; 199:1688–90.
37. Watanabe K, Gatanaga H, Escueta-de Cadiz A, et al. Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy. PLoS Negl Trop Dis 2011; 5:e1318.
38. McGregor A, Brown M, Thway K, Wright SG. Fulminant amebic colitis following periperal blood mononuclear cell depletion. South Med J 2009; 102:833–4.
39. Yamanaka Y, Kuroda K, Asakura T, et al. Paroxysmal nocturnal haemoglobinuria (PNH) due to Entamoeba histolytica infection. Medicine 2013; 92:495–501.
40. Stark D, van Hal S, Fotedar R, et al. Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis. J Clin Microbiol 2008; 46:1678–81.
41. Prim N, Escamilla P, Solé R, et al. Risk of underdiagnosing amebic dysentery due to false-negative Entamoeba histolytica antigen detection. Diagn Microbiol Infect Dis 2012; 73:372–3.
42. Ryan U, Paparini A, Oskam C. New technologies for detection of enteric parasites. Trends Parasitol 2017; 33:532–46.
43. Qvarnstrom Y, James C, Kayarong M, et al. Comparison of real-time PCR protocols for differential laboratory diagnosis of amebiasis. J Clin Microbiol 2005; 43:5491–7.
44. Gonzales MI, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009: CD006085.
45. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101:1025–31.
46. Kimura M, Nakamura T, Nawa Y. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am J Trop Med Hyg 2007; 77:381–5.
47. Capparelli EV, Bricker-Ford R, Rogers MJ, et al. Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrob Agents Chemother. In press.
48. Alvarado-Esquivel C, Hernández-Tinoco J, Francisco Sánchez-Anguiano L, et al. Serosurvey of Entamoeba histolytica exposure among tepehuanos population in Durango, Mexico. Int J Biomed Sci 2015; 11:61–6.
49. Alam MA, Maqbool A, Nazir MM, et al. Prevalence of Entamoeba histolytica-like cysts compared to E. histolytica antigens detected by ELISA in the stools of 600 patients from three socioeconomic communities in the Metropolitan City of Lahore, Pakistan. J Parasitol 2015; 101:236–9.
50. Chin YT, Lim YA, Chong CW, et al. Prevalence and risk factors of intestinal parasitism among two indigenous sub-ethnic groups in peninsular Malaysia. Infect Dis Poverty 2016; 5:77.
51. James R, Barratt J, Marriott D, et al. Seroprevalence of Entamoeba histolytica infection among men who have sex with men in Sydney, Australia. Am J Trop Med Hyg 2010; 83:914–6.
52. Platts-Mills TA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015; 3:e564–75.
53. Ozin Y, Kilic MZ, Nadir I, et al. Presence and diagnosis of amebic infestation in Turkish patients with active ulcerative colitis. Eur J Intern Med 2009; 20:545–7.
54. Al-Areeqi MA, Sady H, Al-Mekhlafi HM, et al. First molecular epidemiology of Entamoeba histolytica, E. dispar and E. moshkovskii infections in Yemen: different species-specific associated risk factors. Trop Med Int Health 2017; 22:493–504.
55. Abd-Alla MD, Ravdin JJ. Diagnosis of amoebic colitis by antigen capture ELISA in patients presenting with acute diarrhoea in Cairo, Egypt. Trop Med Int Health 2002; 7:365–70.
56. Samie A, Barrett LJ, Bessong PO, et al. Seroprevalence of Entamoeba histolytica in the context of HIV and AIDS: the case of Vhembe district, in South Africa’s Limpopo province. Ann Trop Med Parasitol 2010; 104:55–63.
57. Abramowicz J, ed. Drugs for Parasitic Infections. 2nd ed. New Rochelle, NY: The Medical Letter, 2010.